(Q43577538)

24 November 2017

Association between selective serotonin-reuptake inhibitor therapy and heart valve regurgitation (English)

1 reference

24 November 2017

0 references

5

Califf RM

1 reference

24 November 2017

Mast ST

1

1 reference

24 November 2017

Gersing KR

2

1 reference

24 November 2017

Anstrom KJ

3

1 reference

24 November 2017

Krishnan KR

4

1 reference

24 November 2017

Jollis JG

6

1 reference

24 November 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

American Journal of Cardiology

24 November 2017

1 reference

24 November 2017

87

1 reference

24 November 2017

8

1 reference

24 November 2017

989-93: A4

1 reference

Valvular heart disease associated with fenfluramine-phentermine

24 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901435-7

A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901435-7

The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901435-7

An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901435-7

Making medicines safer--the need for an independent drug safety board.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901435-7

Detailed examination of fenfluramine-phentermine users with valve abnormalities identified in Fargo, North Dakota

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901435-7

Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901435-7

Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901435-7

Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901435-7

Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901435-7

Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901435-7

Neurobiological mechanisms involved in antidepressant therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901435-7

Estimating causal effects from large data sets using propensity scores

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901435-7

Evaluation of aortic insufficiency by Doppler color flow mapping

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901435-7

Color Doppler assessment of mitral regurgitation with orthogonal planes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901435-7

The Measurement of Observer Agreement for Categorical Data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901435-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2901435-7

10.1016/S0002-9149(01)01435-7

7 January 2021

Identifiers

DOI

1 reference

24 November 2017

1 reference